Daclatasvir + Simvastatin = Precautionary

Effect on Concentration

Daclatasvir
No change
Applies within class?
No
Simvastatin
Increase
Applies within class?
No

Pharmacologic Effects

Daclatasvir
Effect
N/A
Applies within class?
No
Simvastatin
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 09-Jul-2018

Summary

Caution is advised during coadministration of daclatasvir with simvastatin and other substrates of OATP1B1 or BCRP transporters, as daclatasvir is an inhibitor. The authors state that daclatasvir may increase exposure of simvastatin, therefore close monitoring is warranted Caution is advised when utilizing this combination, but formal dosing recommendations are not available.

Sources

Daclatasvir vs Simvastatin ^

Study Design

*This interaction has not been formerly studied, but inferences are drawn from knowledge of the metabolic and transport pathways of each of the drugs.

Study Results

The manufacturer states that coadministration of daclatasvir with inhibitors or inducers of either CYP3A or P-gP may alter daclatasvir concentrations.

Study Conclusions

Inhibitors of P-gP or CYP3A may increase daclatasvir concentrations, while inducers of this enzyme and transport protein may decrease daclatasvir concentrations.

References

Garimella T, You X, Wang R, Huang SP, Kandoussi H, Biffano M, Eley T. A review of daclatasvir drug-drug interactions. Advances In Therapy. 2016; 11: 1867-1884.